Digitisation | June 22, 2022
Iktos and Zealand Pharma to develop AI technology for peptide drug design
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Tislelizumab is now approved in nine indications in China
Bayer now present in four of the largest biotechnology hubs in the United States
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Subscribe To Our Newsletter & Stay Updated
